Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Drug Pipeline

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. maintains a substantial clinical development portfolio, with 71 active trials out of 155 total trials registered since 2008. These active programs span from Phase 1 through Phase 4, with 29, 31, 21, and 2 trials in each phase, respectively. The company’s research is distributed across six therapeutic areas, but is heavily concentrated in oncology, which accounts for 63% of active programs (45 trials). Within oncology, the leading indications are solid tumor (advanced) with eight active trials including two in Phase 3, breast cancer with five active trials including two in Phase 3, myelofibrosis with four active trials, non-Hodgkin lymphoma with four active trials including one in Phase 3, and NSCLC with three active trials including two in Phase 3. Beyond oncology, the portfolio includes active trials in respiratory (6), immunology (5), infectious disease (4), rare disease (2), and metabolic (1) indications. The high proportion of oncology trials, and the presence of multiple Phase 3 programs within that therapeutic area, suggest a focus on near-term catalysts in that space.